Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable. METHODS: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory-confirmed Covid-19 and safety, which were both evaluated through 6 months after vaccination. RESULTS: BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. CONCLUSIONS: Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, these clinical trials only included cases of the original and alpha variants and did not include the latter variants such as Delta and Omicron.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of the vaccine at preventing COVID-19 infection in individuals aged 16 was 95%, and over the six subsequent months, vaccine efficacy was 91.3%.385–387”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [386]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“protection against infection starts to wane within a few months of administration.8–11”
From Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the studies with longer follow-up, Thomas et al. [28] and El Sahly et al. [29] reported mRNA vaccine efficacy of 91–93% against laboratory-confirmed SARS-CoV-2 infection and 97–98% against severe disease.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Vaccine efficacy against Covid-19 from 7 days to 6 months after the second dose was 91%,6 with a similar estimated real-world effectiveness from 8 to 28 days after the second dose.7”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citation
Cited by
Items 501–600 of 1,004
Rovida, F., Esposito, G. L., Rissone, M., Novelli, V., Cutti, S., Muzzi, A., Rona, C., Bertoli, E., Daglio, M., Piralla, A., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.06.028 · Cited by 15
Comparative COVID-19 Vaccine Effectiveness Over Time in Veterans
Mayr, F., Talisa, V. B., Shaikh, O. S., Omer, S. B., Butt, A. A., & Yende, S. P. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac311 · Cited by 16
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Niesen, M. J. M., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Gordon, J. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac082 · Cited by 18
Homan, T., Mazzilli, S., Chieti, A., Musa, A., Roth, A., Fortunato, F., Bisceglia, L., Prato, R., Lopalco, P. L., & Martinelli, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-23235-4 · Cited by 16
Mohraz, M., Vahdat, K., Ghamari, S., Abbasi‐Kangevari, M., Ghasemi, E., Ghabdian, Y., Rezaei, N., Pouya, M. A., Abdoli, A., Malekpour, M., et al. (2023) · BMJ · doi:10.1136/bmj-2023-070464 · Cited by 16
Ding, H., Xia, Q., Shen, J., Zhu, C., Zhang, Y., & Feng, N. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113607 · Cited by 16
Jiang, W., Maldeney, A. R., Yuan, X., Richer, M. J., Renshaw, S. E., & Luo, W. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113665 · Cited by 17
Beyond COVID-19: the promise of next-generation coronavirus vaccines
Mukesh, R. K., Yinda, C. K., Munster, V. J., & van Doremalen, N. (2024) · npj Viruses · doi:10.1038/s44298-024-00043-3 · Cited by 17
“During the initial COVID-19 waves, multiple vaccines were shown to provide partial protection from infection, severe disease, and death 105 – 107 . mRNA-1273 and BNT162b2 vaccines, both mRNA vaccines, showed more than 90% ef fi cacy in preventing symptomatic infection and disease severity 108,109 .”
Guo, C. M., Chai, X., Baerlike, M., Liu, Y., Wang, Y., Shao, F., Huang, Q., Zhang, W., Cen, S., Dong, Y., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.09.002 · Cited by 17
Kahn, B., Apostolidis, S. A., Bhatt, V., Greenplate, A. R., Kallish, S., LaCava, A. F., Lucas, A., Meyer, N. J., Negoianu, D., Ogdie, A., et al. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000578 · Cited by 16
Ferreira, C. D. S., Dantés, H. G., Bellei, N., López, E. L., Crespo, K. A. N., O’Ryan, M., & Villegas, J. (2021) · Viruses · doi:10.3390/v13122391 · Cited by 18
Considerations for the Safe Operation of Schools During the Coronavirus Pandemic
Lordan, R., Prior, S., Hennessy, E. J., Naik, A. S., Ghosh, S., Paschos, G. K., Skarke, C., Barekat, K., Hollingsworth, T., Juska, S. A., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.751451 · Cited by 18
Peralta-Amaro, A. L., Tejada-Ruíz, M. I., Rivera-Alvarado, K. L., Cobos-Quevedo, O., Romero-Hernández, P., Macías-Arroyo, W., Avendaño-Ponce, A., Hurtado-Díaz, J., Lastra, O. L. V., & Hernández, A. L. (2022) · Vaccines · doi:10.3390/vaccines10010126 · Cited by 16
There is nothing exempt from the peril of mutation – The Omicron spike
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Anwer, M. K., Makeen, H. A., Albratty, M., Alhazmi, H. A., Bhatia, S., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112756 · Cited by 16
“Information from about 44,000 people was collected by a recent Pfizer investigation [51], which”
Leclerc, M., Redjoul, R., Bouter, A. L., Beckerich, F., Robin, C., Parinet, V., Pautas, C., Menouche, D., Bouledroua, S., Roy, L., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01250-2 · Cited by 16
“However, similar to the general population [12], IgG(S-RBD) titers tended to decrease over time and at 6 months, only 72% of recipients retained a protective level of IgG(S-RBD), validating the need for a booster shot.”
BackgroundSharma, A., Oda, G., & Holodniy, M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac325 · Cited by 17
“3 Background 1 Messenger RNA (mRNA) based vaccines have demonstrated significant protection 2 against COVID-19 compared to unvaccinated persons in clinical as well as in observational 3 studies [1-4].”
Jugler, C., Sun, H., Grill, F. J., Kibler, K. V., Esqueda, A., Lai, H., Li, Y., Lake, D. F., & Chen, Q. (2022) · Vaccines · doi:10.3390/vaccines10050772 · Cited by 17
“Although several vaccines are available that are effective at preventing severe disease [3,4], the persistence of SARS-CoV-2 infections and the emergence of variants of concern urges the continual development of prophylactics and therapeutics that can be used to treat infected individuals or prevent infections in peop…”
BackgroundRichard, S. A., Epsi, N. J., Lindholm, D. A., Malloy, A. M. W., Maves, R. C., Berjohn, C. M., Lalani, T., Smith, A. G., Mody, R. M., Ganesan, A., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac275 · Cited by 16
Breakthrough SARS-CoV-2 infections after COVID-19 immunization
Hirsh, J., Htay, T., Bhalla, S., Nguyen, V. T., & Cervantes, J. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002131 · Cited by 16
Werner, J., Brandi, G., Jelčić, I., & Galovic, M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.946644 · Cited by 16
“Adverse effects of SARS-CoV-2 vaccination with mRNA vaccines are rare and mostly limited to local reactions or slight systemic symptoms (1) including fatigue and headache most commonly.”
BackgroundLee, B., Ko, J., Lee, K. H., Kim, Y. C., Song, Y. G., Park, Y. S., Baek, Y. J., Ahn, J. Y., Choi, J. Y., Song, K., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02669-22 · Cited by 16
Jugler, C., Sun, H., Nguyen, K., Palt, R., Felder, M., Steinkellner, H., & Chen, Q. (2022) · Plant Biotechnology Journal · doi:10.1111/pbi.13970 · Cited by 18
“Vaccine development against SARS-CoV-2 proceeded at an unprecedented pace and has resulted in multiple effective products, even against emerging variants (Carre~no et al., 2021; Garcia-Beltran et al., 2022; Hager et al., 2022; Heath et al., 2021; El Sahly et al., 2021; Thomas et al., 2021).”
BackgroundKalyoncu, S., Yılmaz, S., Kuyucu, A. Z., Sayili, D., Mert, O., Soytürk, H., Gullu, S., Akinturk, H., Çıtak, E., Arslan, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-32021-9 · Cited by 16
Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 20
Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization
Saha, T., Sinha, S., Harfoot, R., Quiñones‐Mateu, M. E., & Das, S. C. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123411 · Cited by 19
Jaiswal, V., Mukherjee, D., Ang, S. P., Kainth, T., Naz, S., Shrestha, A. B., Agrawal, V., Mitra, S., Chia, J. E., Jilma, B., et al. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101280 · Cited by 17
“The advent of wide-spread vaccination has decreased the rate of infection spread, the severity of COVID-19, and mortality [2,3].”
BackgroundmRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13974 · Cited by 16
Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
Lake, D. F., Roeder, A. J., González‐Moa, M. J., Koehler, M. A., Kaleta, E. J., Jasbi, P., Vanderhoof, J., McKechnie, D., Forman, J., Edwards, B. A., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00151-2 · Cited by 16
“357 Previous reports indicate that NAb levels decline much more rapidly than protection from 358 hospitalization and disease,(12,22) but that does not account for vaccine recipients who never 359 generated high levels of NAbs after two doses.”
BackgroundAvusuglo, W., Bragazzi, N. L., Asgary, A., Orbinski, J., Wu, J., & Kong, J. D. (2021) · Scientific Reports · doi:10.1038/s41598-023-39723-0 · Cited by 16
“43 ) as at the time of study there is not conclusive evidence on the vaccine efficacy; this assumes vaccinated individuals have received two doses.”
BackgroundSerious harms of the COVID-19 vaccines: a systematic reviewPreprint
Gøtzsche, P. C., & Demasi, M. (2022) · medRxiv · doi:10.1101/2022.12.06.22283145 · Cited by 19
Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
Alesci, A., Gitto, M., Kotańska, M., Cascio, P. L., Miller, A., Nicosia, N., Fumia, A., & Pergolizzi, S. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.08.004 · Cited by 15
Singh, O. N., Berry, U., Joshi, G., Asuru, T. R., Chandrasekar, K., Narayanan, S., Srivastava, P., Tiwari, M., Chattopadhyay, S., Mehdi, F., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113498 · Cited by 17
“1,2,8 12 Linear mRNA-encoding the vaccine antigen is generally small in size (compared to the SAM), contains a methyl-guanosine cap analog at the 5 ′ ’-end, poly A-tailed at the 3 ′ ’-end, and the anti-gen-encoding sequence is flanked by untranslated regions (UTR) at both sides.”
Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity
Liao, H., Wu, W.-L., Chiang, C.-Y., Huang, M., Shen, K., Huang, Y., Wu, S., Liao, C., Chen, H., & Liu, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094902 · Cited by 15
Bert, F., Scaioli, G., Vola, L., Accortanzo, D., Moro, G. L., & Siliquini, R. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127233 · Cited by 17
“Four countries (Belgium, France, Germany and Ireland) chose to administer preferably the mRNA vaccine Comirnaty-Pfizer/BioNTech to people younger than 30 years old; four countries (Australia, Chile, Costa Rica, New Zealand) did not use the mRNA vaccine Spikevax-Moderna at all; two countries (Czech Republic and Cyprus)…”
MethodInfluentialSui, Y., Li, J., Andersen, H., Zhang, R., Prabhu, S. K., Hoang, T. N., Venzon, D. J., Cook, A., Brown, R., Teow, E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac091 · Cited by 17
Herpetic Eye Disease Following the SARS-CoV-2 Vaccinations
Cohen, S., Olshaker, H., Fischer, N., Vishnevskia‐Dai, V., Hagin, D., Rosenblatt, A., Zur, D., & Habot‐Wilner, Z. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2103831 · Cited by 15
de Bock, E., Herman, E. S., Bastian, O. W., Filipe, M. D., Vriens, M. R., & Richir, M. C. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101859 · Cited by 15
Tran, B. X., Do, A. L., Boyer, L., Auquier, P., Le, H. T., Vu, M. N. L., Dang, T. H. T., Cao, K. M., Le, L. D. T., Cu, L. T. N., et al. (2022) · JMIR Public Health and Surveillance · doi:10.2196/43055 · Cited by 16
“Immunological studies have also shown a steady decline in antibody levels in people who have been vaccinated against COVID-19, and suggest an increased risk of an infection outbreak [16,17].”
BackgroundZhang, R., Chan, K., Wang, P., Zhou, R., Yau, H. K.-C., Wong, C. K.-W., Au, M. W.-L., Tam, A. R., Ng, C. T., Lou, M. K.-C., et al. (2023) · Vaccines · doi:10.3390/vaccines11040723 · Cited by 15
The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control
MacIntyre, C. R., Costantino, V., & Chanmugam, A. S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.102 · Cited by 15
Yuniar, C. T., Pratiwi, B., Ihsan, A. F., Laksono, B. T., Risfayanti, I., Fathadina, A., Jeong, Y., & Kim, E. Y. (2022) · Vaccines · doi:10.3390/vaccines10020313 · Cited by 16
“The authors rarely reported subgroup analysis and exploratory analysis for harms (25%), only 15 studies reported the subgroup analysis [17,22,24,32,36,37,40,50,58,60,68,70,71,73,74].”
BackgroundJalkanen, P., Kolehmainen, P., Haveri, A., Huttunen, M., Laine, L., Österlund, P., Tähtinen, P. A., Ivaska, L., Maljanen, S., Reinholm, A., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02252-21 · Cited by 15
“Recently, results of a clinical trial with 6 months follow-up on BNT162b2 vaccinees showed 86–100% vaccine efficacy against COVID-19 disease from 7 days after the second dose to the end of the surveillance period (27).”
BackgroundCOVID boosters for wealthy nations spark outrage
Maxmen, A. (2021) · Nature · doi:10.1038/d41586-021-02109-1 · Cited by 15
Hueda-Zavaleta, M., de la Torre, J. C. G., Cáceres-DelAguila, J. A., Muro-Rojo, C., Cruz-Escurra, N. D. L., Siles, D. A., Minchón-Vizconde, D., Corzo, C. A. C., Bardales-Silva, F., Benites-Zapata, V. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10040502 · Cited by 15
“This reduction of the efficacy over time and the raising of SARS-Cov2 variants [8,11,12] has motivated many countries to approve a booster vaccine dose (homologous or heterologous) against COVID-19, after a not standardized period, in previously vaccinated patients.”
BackgroundSafety and Efficacy of COVID-19 Vaccine in Africa: Systematic Review
Mengstu, S., & Berha, A. B. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s401074 · Cited by 14
“5 to 100) was observed.(15) A study done by Moreira et al on results of a third dose of the BNT162b2 vaccine; relative vaccine efficacy of South Africa participants; it was 100.”
MethodArashiro, T., Arima, Y., Kuramochi, J., Muraoka, H., Sato, A., Chubachi, K., Oba, K., Yanai, A., Arioka, H., Uehara, Y., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.021 · Cited by 14
Zewdie, A., Nigusie, A., & Wolde, M. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09697-z · Cited by 15
“Although vaccines are the most effective strategy for disease con-trol, their production processes are very long and require a much higher vaccination rate to reach ‘herd immunity to control the pandemic [11].”
BackgroundBooster or additional vaccination doses in patients vaccinated against COVID-19
Botella, A. G., García‐Lledó, A., Gómez‐Pavón, J., del Castillo, J. M. G., Hernández‐Sampelayo, T., Delgado, M. C. M., Martín‐Sánchez, F. J., Martínez‐Sellés, M., Molero, J., Guillén, S. M., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/149.2021 · Cited by 14
“These data extend those reported in the clinical trial with the mRNA Pfizer’s vaccine in which follow-up was limited to two months [3].”
ResultPeterhoff, D., Einhauser, S., Beileke, S., Niller, H.-H., Günther, F., Schachtner, M., Asbach, B., Steininger, P. A., Tenbusch, M., Peter, A. S., et al. (2022) · Vaccines · doi:10.3390/vaccines10020324 · Cited by 14
Perry, M., Gravenor, M., Cottrell, S., Bedston, S., Roberts, R., Williams, C., Salmon, J., Lyons, J., Akbari, A., Lyons, R., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2031774 · Cited by 12
Case of acquired haemophilia a in Southeast Asia following COVID-19 vaccine
Vuen, L. A., Su-Yin, E. A., Kori, A. N., & Shah, T. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-246922 · Cited by 14
Jeewandara, C., Aberathna, I. S., Gomes, L., Pushpakumara, P. D., Danasekara, S., Guruge, D., Ranasinghe, T., Gunasekera, B., Kamaladasa, A., Kuruppu, H., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.592 · Cited by 14
Cost-effectiveness analysis of COVID-19 vaccination in Poland
Orlewska, K., Wierzba, W., & Śliwczyński, A. M. (2021) · Archives of Medical Science · doi:10.5114/aoms/144626 · Cited by 16
“7% from 4 months after the second dose to the data cut-off date – an average decline of approximately 6% every 2 months [24].”
BackgroundSmith, L., Shin, J. I., & Koyanagi, A. (2022) · Life Cycle · doi:10.54724/lc.2022.e5 · Cited by 16
“Institute of Allergy and Infectious Diseases by the National Institutes of Health [5], and was proven to be effective with two doses 28 days apart.[4] Further studies have indicated that they are also effective in binding and the development of neutralizing antibodies and angiotensin-”
BackgroundInfluentialCharonis, S. A., James, L. M., & Georgopoulos, A. P. (2022) · Scientific Reports · doi:10.1038/s41598-022-11956-5 · Cited by 15
Syrigos, N. K., Κόλλιας, Α., Grapsa, D., Fyta, E., Kyriakoulis, K. G., Vathiotis, I. A., Kotteas, E. A., & Syrigou, E. I. (2022) · Vaccines · doi:10.3390/vaccines10050745 · Cited by 14
Immunologic response to SARS-CoV-2 mRNA vaccination in pediatric kidney transplant recipients
Kermond, R., Ozimek-Kulik, J. E., Kim, S., Alexander, S. I., Hahn, D., Kesson, A. M., Wood, N., McCarthy, H. J., & Durkan, A. M. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05679-y · Cited by 14
“SARS-CoV-2 vaccines have been shown to be safe and efficacious in lowering the rates of SARS-CoV-2 infection, intensive care unit (ICU) admissions, and death in previously healthy adults [11, 12].”
BackgroundClinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Levine, S., François, F., Iturrate, E., Wang, G., Dittmann, M., Lighter, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104141 · Cited by 15
Rammauro, F., Carrión, F., Olivero‐Deibe, N., Fló, M., Ferreira, A., Pritsch, O., & Bianchi, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.023 · Cited by 14
“Safety and efficacy of BNT162b2 and CoronaVac vaccines have been previously reported [5,17,18], and some studies have directly compared CoronaVac and BNT162b2 vaccines performances [19,20].”
Manali, M., Bissett, L. A., Amat, J. A. R., Logan, N. A., Scott, S., Hughes, E. C., Harvey, W. T., Orton, R. J., Thomson, E. C., Gunson, R. N., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac332 · Cited by 14
“does not elicit lifelong immunity [18, 19] but instead result in a variety of immune phenotypes, which are likely to influence both transmission dynamics and disease outcomes.”
Huang, J., Xia, L., Tian, L., Fan, H., Xu, D., Ai, X., Wu, X., Chen, J., Xing, G., Huang, L., et al. (2022) · Biological Research · doi:10.1186/s40659-022-00395-1 · Cited by 14
Levi, N., Moravsky, G., Weitsman, T., Amsalem, I., Itach, S. B., Algur, N., Lapidus, I., Mitz, O., Glikson, M., Weil‐Weiner, Y., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2687 · Cited by 14
Tani, N., Ikematsu, H., Goto, T., Gondo, K., Inoue, T., Yanagihara, Y., Kurata, Y., Oishi, R., Minami, J., Onozawa, K., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac493 · Cited by 15
“Around 15% of vaccinees had fever after the second or third dose of an mRNA COVID-19 vaccine [1, 9, 10], while only 1%–2% did so after influenza or pneumococcal vaccination [11, 12].”
BackgroundWang, Q., Ning, J., Chen, Y., Li, B., Shi, L., He, T., Zhang, F., Chen, X., Zhai, A., & Wu, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008420 · Cited by 15
COVID-19 vaccination and liver disease
Ozaka, S., Kobayashi, T., Mizukami, K., & Murakami, K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6791 · Cited by 14
Bai, A. D., Jiang, Y., Nguyen, D. L., Lo, C. K. L., Stefanova, I. Z., Guo, K., Wang, F., Zhang, C., Sayeau, K., Garg, A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.53301 · Cited by 15
Ueno, M., Takabatake, H., Itakura, J., Fujita, R., Kayahara, T., Morimoto, Y., Notohara, K., & Mizuno, M. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01794-x · Cited by 14
Current challenges and perspectives in lung cancer care during COVID-19 waves
Mariniello, D. F., Aronne, L., Vitale, M., Schiattarella, A., Pagliaro, R., & Komici, K. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000967 · Cited by 15
Morgan, A. K., Aziire, M. A., Cobbold, J., Agbobada, A. A., & Kudzawu, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2211495 · Cited by 16
Ong, S. W. X., Goh, Y. S., Torres‐Ruesta, A., Chang, Z. W., Chan, Y., Neo, V. K., Lee, B. T. K., Duan, K., Amrun, S. N., Yeo, N. K., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28774 · Cited by 14
Al-Haideri, M. T., Mannani, R., Kaboli, R., Gharebakhshi, F., Darvishzadehdeldari, S., Tahmasebi, S., Faramarzi, F., Cotrina-Aliaga, J. C., Khorasani, S., Alimohammadi, M., et al. (2023) · Transplant Immunology · doi:10.1016/j.trim.2023.101858 · Cited by 14
From COVID-19 Vaccine Hesitancy to Vaccine Acceptance: Results of a Longitudinal Survey
Fisher, K. A., Nguyen, N. T. T., Fouayzi, H., Crawford, S. L., Singh, S., Dong, M., Wittenberg, R., & Mazor, K. M. (2023) · Public Health Reports · doi:10.1177/00333549231176006 · Cited by 15
Katoto, P. D., Tamuzi, J. L., Brand, A., Marangu, D., Byamungu, L. N., Wiysonge, C. S., & Gray, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2214495 · Cited by 14
Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination
Sekulovski, M., Mileva, N. B., Vasilev, G., Miteva, D., Gulinac, M., Peshevska-Sekulovska, M., Chervenkov, L., Batselova, H., Vasilev, G., Tomov, L., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102813 · Cited by 15
Unlocking the potential of RNA-based therapeutics in the lung: current status and future directions
Man, H. S. J., Moosa, V. A., Singh, A. N., Wu, L., Granton, J. T., Juvet, S., Hoang, C. D., & de Perrot, M. E. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1281538 · Cited by 15
Paul, É., Brown, G. W., Ridde, V., & Sturmberg, J. P. (2024) · Public Health in Practice · doi:10.1016/j.puhip.2024.100493 · Cited by 14
“Third, science – based on the individual clinical trials – showed a good safety profile of Covid-19 mRNA vaccines [25,27].”
BackgroundInfluentialBreakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021Preprint
Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y., & Wallace, A. W. (2021) · medRxiv · doi:10.1101/2021.10.13.21264966 · Cited by 14
Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction
Marabotti, C. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2067531 · Cited by 13
“Nevertheless, very recent papers reporting five to six-months update on BNT162b2 and mRNA1273 (ModernaNIH) vaccines [14,15], actually gives the measure of the dependence of ARR on the time of observation, showing an increase of ARR up to 3.”
BackgroundSuarez Castillo, M., Khaoua, H., & Courtejoie, N. (2022) · Global Epidemiology · doi:10.1016/j.gloepi.2022.100076 · Cited by 13
Xu, X., Cui, L., Zhang, Y., & Gu, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.023 · Cited by 13
Self-citationBNT162b2 Vaccine Booster and Covid-19 Mortality. Reply.
Arbel, R., Sergienko, R., & Hammerman, A. (2022) · PubMed · doi:10.1056/nejmc2120044 · Cited by 13
BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
Walter, E. B., Talaat, K. R., & Gurtman, A. (2022) · PubMed · doi:10.1056/nejmc2118775 · Cited by 13
McClary, W. D., Brandt, D. S., Jennewein, M. F., Singh, J., Beaver, S., Ykema, M., Press, C., Melief, E. H., Bakken, J., Fusco, P., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114054 · Cited by 13
Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation
Kim, C., Lee, Y., Lee, H., & Kim, B. (2025) · Small Methods · doi:10.1002/smtd.202501401 · Cited by 14
Chan, E. W. W., Leung, M. T. Y., Lau, L. K. W., Leung, J. C. N., Lum, D. H., Wong, R. S. M., Li, X., Chui, C. S. L., Wan, E. Y. F., Wong, C. K. H., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.12.354 · Cited by 13
Clavero, R., Parra-Lucares, A., Méndez-Valdés, G., Villa, E., Bravo, K., Mondaca, E., Aranda, J., Brignardello, R., Gajardo, C., Ordenes, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10091542 · Cited by 12
“All these vaccines have demonstrated a reduction in COVID-19 and adverse outcomes, including hospitalizations and deaths [5,7,8].”
BackgroundThree for me and none for you? An ethical argument for delaying COVID-19 boosters
Jecker, N. S., & Lederman, Z. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2021-107824 · Cited by 13
Multiple Sclerosis, COVID-19 and Vaccines: Making the Point
Toscano, S., Chisari, C. G., & Patti, F. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00288-7 · Cited by 14
Identification of Vaccine Effects When Exposure Status Is Unknown
Stensrud, M. J., & Smith, L. H. (2023) · Epidemiology · doi:10.1097/ede.0000000000001573 · Cited by 13
“Often the most commonly reported and publicized results are relative effects, as in major studies on different COVID-19 vaccines [40,42,43].”
ResultReview of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine
Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12010057 · Cited by 13
“With the peak of 96% within 2 months from 7 days after the second injection, the vaccine efficacy gradually declines to 83% at between 4 to 6 months after the second dose, with a decline of approximately 6% every 2 months [96].”
BackgroundA review on COVID-19 transmission, epidemiological features, prevention and vaccination
Zhang, Y., Wu, G., Chen, S., Xu, J., Yimaer, W., Zhang, W., Lin, S. C. C., Hao, Y., Gu, J., & Li, J. (2022) · Medical Review · doi:10.1515/mr-2021-0023 · Cited by 15
Adults hospitalized with breakthrough COVID‐19 have lower mortality than matched unvaccinated adults
Myers, L. C., Kipnis, P., Greene, J., Lawson, B. L., Escobar, G. J., FIREMAN, B. H., Klein, N. P., & Liu, V. X. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13504 · Cited by 13
Oliveira-Silva, J., Reis, T., Lopes, C., Batista-Silva, R., Ribeiro, R. J. T., Marques, G., Pacheco, V., Rodrigues, T., Afonso, A., Pinheiro, V. C. A., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.05.026 · Cited by 13
Expression of NAC1 Restrains the Memory Formation of CD8+ T Cells during Viral Infection
Wang, L., Kumar, A., Das, J. K., Ren, Y., Peng, H., Ballard, D. J., Xiong, X., Davis, J. R., Ren, X., Yang, J., et al. (2022) · Viruses · doi:10.3390/v14081713 · Cited by 13
“For example, the effectiveness of the COVID-19 vaccine had been proved to gradually decrease after 5–6 months among fully vaccinated people [24,25].”
BackgroundEpidemiological aspects of headache after different types of COVID ‐19 vaccines: An online survey
Magdy, R., Khedr, D. M., Yacoub, O., Attia, A., Abdelrahman, M. A., & Mekkawy, D. (2022) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14374 · Cited by 14
Vogrig, M., Berger, A.-E., Bourlet, T., Waeckel, L., Haccourt, A., Chanavat, A. H., Hupin, D., Roche, F., Botelho-Nevers, É., Pozzetto, B., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01354-x · Cited by 14
Ando, M., Satonaga, Y., Takaki, R., Yabe, M., Kan, T., Omote, E., Yamasaki, T., Komiya, K., & Hiramatsu, K. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.09.019 · Cited by 13
Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
Takeshita, M., Fukuyama, H., Kamada, K., Matsumoto, T., Makino‐Okamura, C., Uchikubo‐Kamo, T., Tomabechi, Y., Hanada, K., Moriyama, S., Takahashi, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105596 · Cited by 13
“Various vaccines have been developed against theWuhan strains and, fortunately, they have shown efficacy against variants.(5) Although the number of cases has decreased in some countries, probably due to vaccine effectiveness, the global pandemic has not yet been terminated.”
SARS-COV-2 infections in inborn errors of immunity: A single center study
Cousins, K. L., DeFelice, N., Jeong, S., Feng, J., Lee, A. S. E., Rotella, K., Sanchez, D., Jaber, F., Agarwal, S., Ho, H.-E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035571 · Cited by 13
“Vaccinations for COVID-19 became available, starting with BNT162b2 (Pfizer) (17) which was granted emergency use authorization (EUA) on December 11, 2021.”
BackgroundMossadeq, S., Shah, R., Shah, V., & Bagul, M. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02455-x · Cited by 13
Metadata
- Authors
- Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Yang, Q., Liberator, P., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Gruber, W. C., & Jansen, K. U.
- Affiliations
- Pfizer (United States) (US)
- From the State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., S.B., W.V.K., D.C., Q.Y., P.L., P.R.D., W.C.G., K.U.J.) — both in New York; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and iTrials-Hospital Militar Central (G.P.M.) and Fundacion INFANT, Buenos Aires (F.P.P.) — all in Brazil; Centro Paulista de Investigação Clinica, São Paulo (C.Z.); Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., X.X.) and Worldwide Safety, Safety Surveillance, and Risk Management (D.B.T., S.M.), Pfizer, Collegeville, PA; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (Ö.T., U.Ş.) and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Cent...
- Corresponding author
- Absalon, Judith
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-04
- Volume
- 385
- Issue
- 19
- Pages
- 1761-1773
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8461570
- OpenAlex
- W3200157219
- Semantic Scholar
- 1f8a398d84bc89852aee671b48f84e4363399de3
- Cited by
- 1,640
- References
- 28
- Citations by year
- 2026: 57 · 2025: 141 · 2024: 212 · 2023: 343 · 2022: 654 · 2021: 229
- FWCI
- 114.02
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2 spike protein, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, long-term follow-up, waning immunity, severe COVID-19 prevention, B.1.351 variant, emergency use authorization, children and adolescents, adverse events, trial discontinuation
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Child, Female, Follow-Up Studies, Humans, Immunization, Secondary, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.